The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...
The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
Results from the Phase III PSMAddition trial show that adding the radioligand therapy Pluvicto (177Lu-PSMA-617) to androgen ...
Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces ...
New data from the phase 1b DeLLphi-303 study show that adding tarlatamab to first-line chemoimmunotherapy achieved a 71% ...
Results from the phase II LenCabo trial show that lenvatinib plus everolimus significantly prolonged progression-free ...
Findings from the Phase 3 ASCENT-03 trial, presented at ESMO 2025, demonstrated that sacituzumab govitecan (Trodelvy®) significantly reduced the risk of disease progression or death by 38% compared wi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback